...
首页> 外文期刊>International journal of clinical pharmacology and therapeutics >In vivo binding characteristics of phenytoin to serum proteins in monotherapy pediatric patients with epilepsy.
【24h】

In vivo binding characteristics of phenytoin to serum proteins in monotherapy pediatric patients with epilepsy.

机译:苯妥英钠与单药治疗小儿癫痫患者血清蛋白的体内结合特征。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIM: The aim of the present study was to determine the binding characteristics of phenytoin (PHT) to serum proteins in the pediatric population. Binding parameters of PHT to serum proteins in our study were conducted to compare with in vivo or in vitro binding parameters of PHT to serum proteins in adult subjects reported by other investigators. SUBJECTS AND MATERIALS: Serum samples in the study were obtained from 40 pediatric patients (16 male, 24 female) receiving PHT monotherapy. Their age ranged from 1 to 15 years (9.2 +/- 3.6 years, mean +/- SD). The in vivo population binding parameters of PHT to serum proteins and theoretical minimal unbound serum PHT fraction (fu) were determined using an equation derived from the Scatchard equation. RESULTS: The association constant (Ka) was 0.014 l/micromol, while the total concentration of binding sites (n(Pt)) was 747 micromol/l. The number of binding sites per albumin molecule (n) was 1.13, while binding ability (n x Ka) was 0.0161/micromol. The fu was 0.087. The n x Ka is approximately 1.2 times higher in PHT monotherapy adult patients of Pospisil et al. [1992] (i.e. 0.0191 l/micromol) than in all our patients. The association constant is approximately 1.3 times higher in the in vitro study of Monks et al. [1978] (i.e. 0.0186 l/micromol) than in our study, while n is similar between the two studies. The fu in our pediatric patients is similar to the unbound serum PHT fraction in adult patients receiving PHT therapy reported by Richens [1979] (i.e. 0.1). CONCLUSION: Our results suggest that there may be small differences in the binding characteristics of PHT to serum proteins between Japanese pediatric and non-Japanese adult subjects. The unbound serum fraction of PHT in pediatric patients with epilepsy can be assumed to be relatively constant in the therapeutic concentration range of PHT.
机译:目的:本研究的目的是确定苯妥英钠(PHT)与儿科人群血清蛋白的结合特征。在我们的研究中进行了PHT与血清蛋白的结合参数,以与其他研究者报道的成人受试者中PHT与血清蛋白的体内或体外结合参数进行比较。受试者和材料:研究中的血清样本来自接受PHT单药治疗的40名儿科患者(男16例,女24例)。他们的年龄为1到15岁(9.2 +/- 3.6岁,平均+/- SD)。使用从Scatchard方程得出的方程确定PHT与血清蛋白的体内群体结合参数和理论最小未结合血清PHT分数(fu)。结果:缔合常数(Ka)为0.014 l / micromol,而结合位点的总浓度(n(Pt))为747 micromol / l。每个白蛋白分子的结合位点数(n)为1.13,而结合能力(n x Ka)为0.0161 / micromol。 fu为0.087。在Pospisil等人的PHT单药成年患者中,n x Ka大约高1.2倍。 [1992](即0.0191 l / micromol)高于我们所有的患者。在Monks等人的体外研究中,缔合常数大约高1.3倍。 [1978](即0.0186 l / micromol)低于我们的研究,而两项研究之间的n相似。我们的儿科患者的fu与Richens [1979]报告的接受PHT治疗的成年患者的未结合血清PHT分数相似(即0.1)。结论:我们的结果表明,日本儿童和非日本成人受试者之间PHT与血清蛋白的结合特性可能存在细微差异。小儿癫痫患者的未结合的PHT血清分数可以认为在PHT的治疗浓度范围内相对恒定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号